These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1496998)

  • 1. Smoking and cancer.
    Carbone D
    Am J Med; 1992 Jul; 93(1A):13S-17S. PubMed ID: 1496998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures.
    Husgafvel-Pursiainen K; Ridanpää M; Anttila S; Vainio H
    J Occup Environ Med; 1995 Jan; 37(1):69-76. PubMed ID: 7620945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of genetic and molecular events in the pathogenesis of lung cancer.
    Johnson BE; Kelley MJ
    Chest; 1993 Jan; 103(1 Suppl):1S-3S. PubMed ID: 8380130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment.
    Hussain SP; Hofseth LJ; Harris CC
    Lung Cancer; 2001 Dec; 34 Suppl 2():S7-15. PubMed ID: 11720736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and K-ras mutations in lung cancers from former and never-smoking women.
    Vähäkangas KH; Bennett WP; Castrén K; Welsh JA; Khan MA; Blömeke B; Alavanja MC; Harris CC
    Cancer Res; 2001 Jun; 61(11):4350-6. PubMed ID: 11389059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenes in human lung cancer.
    Kratzke RA; Shimizu E; Kaye FJ
    Cancer Treat Res; 1992; 63():61-85. PubMed ID: 1363367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers.
    Kersting M; Friedl C; Kraus A; Behn M; Pankow W; Schuermann M
    J Clin Oncol; 2000 Sep; 18(18):3221-9. PubMed ID: 10986054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular abnormalities in lung cancer].
    Shimizu S; Mitsudomi T
    Nihon Rinsho; 2002 May; 60 Suppl 5():73-7. PubMed ID: 12101773
    [No Abstract]   [Full Text] [Related]  

  • 10. [Causative agents for lung carcinogenesis].
    Yano S; Sone S
    Nihon Rinsho; 2000 May; 58(5):1017-22. PubMed ID: 10824542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell cycle, tumor suppressor genes and lung cancers].
    Bréchot JM
    Rev Mal Respir; 1998 Sep; 15(4):461-6. PubMed ID: 9805756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of tumor suppressor genes in bladder cancer.
    Cordon-Cardo C; Reuter VE
    Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recessive oncogenes.
    Bookstein R; Allred DC
    Cancer; 1993 Feb; 71(3 Suppl):1179-86. PubMed ID: 8428341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular biology of tobacco smoke associated neoplasia].
    Zojer N; Fritsche R; Fiegl M; Schulte-Hermann R; Mannhalter C; Huber H
    Wien Klin Wochenschr; 1996; 108(18):574-81. PubMed ID: 9012141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and molecular biological aspects of human bronchogenic carcinogenesis.
    Willey JC; Harris CC
    Crit Rev Oncol Hematol; 1990; 10(2):181-209. PubMed ID: 2193649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implication of p53 mutation in lung cancer.
    Campling BG; El-Deiry WS
    Mol Biotechnol; 2003 Jun; 24(2):141-56. PubMed ID: 12746555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
    Le Calvez F; Mukeria A; Hunt JD; Kelm O; Hung RJ; Tanière P; Brennan P; Boffetta P; Zaridze DG; Hainaut P
    Cancer Res; 2005 Jun; 65(12):5076-83. PubMed ID: 15958551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
    Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
    J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer.
    Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT
    Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.